China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx’s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene’s filings for its drugs as companion diagnostics (CDx). This strategic alliance aims to enhance the development and regulatory approval process for BeiGene’s targeted therapies.
AmoyDx: Company Profile and Technology
Founded in 2008, AmoyDx is a leading diagnostic company known for its innovative technologies, including ADx ARMS, Super ARMS, ddCapture, and ADx HANDLE. These technologies have attracted partnerships with major pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Eisai, and Hengrui Medicine. AmoyDx’s HER2 detection kits are designed to provide accurate and reliable diagnostic results, supporting the use of targeted therapies in cancer treatment.
Future Outlook
The partnership between BeiGene and AmoyDx underscores the growing importance of companion diagnostics in the development of targeted cancer therapies. By leveraging AmoyDx’s advanced detection technologies, BeiGene aims to streamline the regulatory approval process for its drugs and enhance the precision of its therapeutic offerings. This collaboration is expected to contribute to improved patient outcomes and the advancement of personalized medicine.-Fineline Info & Tech
